Editas Medicine Inc [NASDAQ: EDIT] jumped around 2199997.75 points on Wednesday, while shares priced at $2200000.0 at the close of the session, up 13.78%.
Editas Medicine Inc stock is now -45.18% down from its year-to-date (YTD) trading value. EDIT Stock saw the intraday high of $2.875 and lowest of $2.235 per share. The company’s 52-week high price is 6.05, which means current price is +181.32% above from all time high which was touched on 02/19/25.
Compared to the average trading volume of 2.20M shares, EDIT reached a trading volume of 9515746 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Editas Medicine Inc [EDIT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EDIT shares is $3.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EDIT stock is a recommendation set at 2.57. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Editas Medicine Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 28, 2025. The new note on the price target was released on December 16, 2024, representing the official price target for Editas Medicine Inc stock. On December 13, 2024, analysts decreased their price target for EDIT shares from 11 to 3.
The Price to Book ratio for the last quarter was 3.43, with the Price to Cash per share for the same quarter was set at 2.64.
How has EDIT stock performed recently?
Editas Medicine Inc [EDIT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 16.89. With this latest performance, EDIT shares gained by 44.63% in over the last four-week period, additionally plugging by 111.57% over the last 6 months – not to mention a rise of 101.57% in the past year of trading.
Editas Medicine Inc [EDIT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Editas Medicine Inc [EDIT] shares currently have an operating margin of -578.30% and a Gross Margin at 82.37%. Editas Medicine Inc’s Net Margin is presently recorded at -701.06%.
Return on Equity for this stock declined to -71.37%, with Return on Assets sitting at -71.37%.
Earnings analysis for Editas Medicine Inc [EDIT]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EDIT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Editas Medicine Inc go to 27.74%.
Insider trade positions for Editas Medicine Inc [EDIT]
There are presently around $57.56%, or 57.76%% of EDIT stock, in the hands of institutional investors. The top three institutional holders of EDIT stocks are: VANGUARD GROUP INC with ownership of 8.03 million shares, which is approximately 9.7589%. BLACKROCK INC., holding 7.78 million shares of the stock with an approximate value of $$36.34 million in EDIT stocks shares; and BLACKROCK INC., currently with $$28.02 million in EDIT stock with ownership which is approximately 7.2895%.
